Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
NCT00338884
Last updated date
ABOUT THIS STUDY
A phase II study to allow patients with advanced kidney cancer access to sunitinib malate
treatment and to find out the good and bad effects of taking 37.5 mg sunitinib malate in a
continuous daily regimen (once per day) for one year.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Cell Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Advanced kidney cancer
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Previous treatment for kidney cancer, except surgical removal of kidney tumor
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Renal Cell CarcinomaAxitinib Therapy Management Study
NCT04555603
- New York, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal Cell CarcinomaA Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
NCT00480935
- Toronto, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal Cell CarcinomaBevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma
NCT00556205
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal Cell CarcinomaA Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma
NCT00788060
- Durham, North Carolina
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer | |||
| Official Title ICMJE | A Phase II Efficacy And Safety Study Of Sunitinib Malate (SU011248) Administered In A Continuous Daily Regimen In Patients With Advanced (First-Line) Renal Cell Cancer | |||
| Brief Summary | A phase II study to allow patients with advanced kidney cancer access to sunitinib malate treatment and to find out the good and bad effects of taking 37.5 mg sunitinib malate in a continuous daily regimen (once per day) for one year. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 2 | |||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
| Condition ICMJE | Carcinoma, Renal Cell | |||
| Intervention ICMJE | Drug: Sunitinib malate
Sunitinib malate starting dose 37.5 mg daily continuous daily schedule | |||
| Study Arms ICMJE | Experimental: SUNITINIB MALATE.
Sunitinib malate starting dose 37.5 mg daily continuous daily schedule Intervention: Drug: Sunitinib malate | |||
| Publications * |
| |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 120 | |||
| Original Enrollment ICMJE | Same as current | |||
| Actual Study Completion Date ICMJE | April 2009 | |||
| Actual Primary Completion Date | April 2009 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | Child, Adult, Older Adult | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | Argentina, Australia, Brazil, Korea, Republic of, Mexico, Taiwan | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00338884 | |||
| Other Study ID Numbers ICMJE | A6181110 | |||
| Has Data Monitoring Committee | Not Provided | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | August 2012 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||